Nivolumab for nasopharyngeal cancer after platinum chemotherapy
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies nivolumab (an immune therapy) for nasopharyngeal cancer that grew or returned after platinum chemotherapy. It aims to shrink tumors or slow cancer growth after standard treatment hasn’t worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18 years
- Your cancer must be squamous cell carcinoma and located in the nasopharynx
- Your cancer must have progressed or returned during platinum chemotherapy or within 6 months after it ended
- You should be well enough to do daily activities (ECOG 0–1)
- Blood tests must be strong enough (for example: hemoglobin, platelets, and neutrophils are above set minimums)
- Your heart, kidney, and liver tests must be within allowed limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer. The goal is to see if adding these drugs improves the chances of controlling the cancer.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
Hear when a new Nasopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.